Clinical Trial Update: A Study to Assess the Efficacy of a Heterologous Prime/Boost Vaccine Regimen of Ad26.Mos4.HIV and Aluminum Phosphate-Adjuvanted Clade C gp140 in Preventing Human Immunodeficiency Virus (HIV) -1 Infection in Women in Sub-Saharan Africa [Phase 2]

View source ↗

Summary

Phase 2 trial examining a heterologous prime/boost HIV vaccine regimen (Ad26.Mos4.HIV and aluminum phosphate-adjuvanted gp140) in women in Sub-Saharan Africa; s…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• Ad26.Mos4.HIV (Adenovirus serotype 26 HIV vaccine (Mosaic))
• Aluminum Phosphate-Adjuvanted Clade C gp140 (gp140 with aluminum phosphate adjuvant)

Snippet

Sponsor: Janssen Vaccines & Prevention B.V. | Conditions: HIV-1 | Phase 2 | Status: TERMINATED | Results posted: 2023-04-18